Trials / Completed
CompletedNCT02791334
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Conditions
- Solid Tumor
- Microsatellite Instability-High (MSI-H) Solid Tumors
- Cutaneous Melanoma
- Pancreatic Cancer
- Breast Cancer (HR+HER2-)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3300054 | Administered IV |
| DRUG | Ramucirumab | Administered IV |
| DRUG | Abemaciclib | Administered orally |
| DRUG | Merestinib | Administered orally |
| DRUG | LY3321367 | Administered IV |
Timeline
- Start date
- 2016-06-29
- Primary completion
- 2020-05-22
- Completion
- 2024-06-27
- First posted
- 2016-06-06
- Last updated
- 2024-09-27
Locations
14 sites across 7 countries: United States, Belgium, Canada, France, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02791334. Inclusion in this directory is not an endorsement.